Search

Displaying results 1001 - 1010 of 8515 in total
  1. Drug

    Dihydroergotamine

    go.drugbank.com/drugs/DB00320
    ApprovedInvestigational

    Dihydroergotamine is used as an abortive therapy for migraines. … [L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile.

  2. Drug

    Doxepin

    go.drugbank.com/drugs/DB01142
    ApprovedInvestigational

    [L5977] Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant.[L5971] However, in 2010 it was approved for the treatment of insomnia. … The latter indication was presented by Pernix Therapeutics.[L5974]

  3. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis. … [L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized

  4. Drug

    Levomefolic acid

    go.drugbank.com/drugs/DB11256
    Approved

    It is available commercially as a crystalline form of the calcium salt (Metafolin(R)), which has the stability required for use as a supplement [A19276]. … Levomefolate is approved as a food additive and is designated a GRAS (generally regarded as safe) compound [L773].

  5. Drug

    Dibotermin alfa

    go.drugbank.com/drugs/DB11639
    ApprovedInvestigational

    Dibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse.

  6. Drug

    Poloxamer 188

    go.drugbank.com/drugs/DB11333
    Approved

    The use of P188 as a potential treatment in different pathological conditions, such as chronic microvascular diseases and skeletal muscle deficiencies, is under investigation [A27217]. … P188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217].

  7. Drug

    L-tartaric acid

    go.drugbank.com/drugs/DB09459
    Approved

    Tartaric acid is a white crystalline organic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics, and is a dihydroxyl derivative ...

    Mixtures: E-Z-gas 2 Granules
  8. Drug

    Cryptenamine

    go.drugbank.com/drugs/DB00785
    Approved

    It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. … Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known.

  9. Drug

    Dapagliflozin

    go.drugbank.com/drugs/DB06292
    ApprovedInvestigational

    [A6757] Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. … Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2.

  10. Drug

    Nitrazepam

    go.drugbank.com/drugs/DB01595
    Approved

    A benzodiazepine derivative used as an anticonvulsant and hypnotic.